In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Record Breaking First Half For Start-Ups Raising Cash In Europe

The first half of 2018 appeared promising for the European biopharma sector, with multiple large investment funds promising cash to young, innovative companies in the region – a turnaround after years of life science firms suffering from a funding drought across Europe.

Growth Financing

Forbion Sees First Close Of New Biotech Fund At €270M In Record Time

With its 2015 third fund Forbion Capital III yielding an internal rate of about 65% and already returning 60% of the money it drew down back to investors, it is probably no surprise that Forbion exceeded its €250M target for its predominantly Europe-focused Forbion IV fund within two months of marketing.

Financing Commercial

BioNTech Signs Rare Disease Co-Development Deal With Genevant & Licenses LNP Platform

BioNTech and Genevant have boosted their clinical ambitions by agreeing a 50/50 co-development, co-commercialization collaboration for five mRNA rare disease programs. BioNTech also secured exclusive licenses to Genevant's LNP drug delivery platform for five oncology programs.

ImmunoOncology Personalized Medicine

Abingworth Closes 12th Life Sciences Fund ABV VII At $315M

European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.

Analysis Commercial

Drayson Outlines Ambition To Build Clinician-Driven AI Business Using NHS Data

Former UK science minister Lord Drayson explains to Scrip his plans for Sensyne Health, an Oxford, UK-based AI-focused healthcare technology company, to go public after securing a second deal with an NHS Foundation Trust while seeking big pharma research collaborations.

Artificial Intelligence Clinical Trials

Teva Retains Top Slot In Generics/Biosimilar Rankings As Industry Faces US Pushback

With Mylan snapping at its heels, Israel’s Teva managed to retain top slot in the latest Generics Bulletin rankings. Severe pricing and margin pressures in the US market made like difficult for generics companies in 2017, with eight of the top 20 firms reporting year on year sales declines.

See All